Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-7: Belantamab mafodotin + bortezomib + dexamethasone vs daratumumab + bortezomib + dexamethasone in relapsed/refractory multiple myeloma
2023-510537-28-00Phase 3Authorised
- Sponsor
- GSK
- Start
- May 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoint: Progression-Free Survival. Planned start May 2020; status: authorised.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-510537-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510537-28-00.